Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 120 publications
Mathematical Biomarkers of Adaptive Therapy Outcomes in Prostate Cancer.
Journal: JAMA oncology
Published: August 06, 2026
Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: April 24, 2026
Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: April 15, 2026
Myosteatosis and Sarcopenic Obesity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Rationale for Mechanism-Driven Multimodal Intervention.
Journal: Cancers
Published: March 17, 2026
Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial.
Journal: Nature communications
Published: February 02, 2026
Direct measurement of Criegee intermediates in isoprene ozonolysis.
Journal: Nature communications
Published: January 30, 2026
H atom product channels in the ultraviolet photodissociation of the 2-methyl-1-propenyl radical.
Journal: Physical chemistry chemical physics : PCCP
Published: January 21, 2026
Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-Preserving Trimodality Therapy.
Journal: The Journal of urology
Published: November 13, 2025
Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinoma.
Journal: Future oncology (London, England)
Published: October 30, 2025
PSA/testosterone ratio as a potential biomarker to identify early progressors of adaptive therapy in metastatic castration sensitive prostate cancer.
Journal: medRxiv : the preprint server for health sciences
Published: July 14, 2025
Different plasma exosome isolation methods generated distinct microRNA and protein profiles in healthy controls and patients with advanced prostate and lung cancer.
Journal: BMC cancer
Published: July 07, 2025
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects.
Journal: Cancer discovery
Published: November 19, 2024
Last Updated: 09/26/2026